AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03707977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01LS
Description: Administered by intravenous (IV) infusion
Study NCT03707977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: Administered by intravenous (IV) infusion
Study NCT02068807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein drops
Description: After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
Study NCT02068807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucose drops
Description: After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
Study NCT04398303 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of MEM-α
Study NCT02625896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
Study NCT02061202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate
Description: inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
Study NCT02061202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo training inhaler with the same instructions as the experimental group.
Study NCT01743079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: LdT 600mg QD
Study NCT01743079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: LAM 100mg QD
Study NCT00853814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access to sedentary behaviors
Description: Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
Study NCT03883633 — intervention group
Intervention type: BEHAVIORAL
Intervention: ReCODE Protocol
Description: Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
Study NCT02683096 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
Study NCT00493922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test
Description: Introduction of rapid diagnostic test for malaria
Study NCT00493922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microscopy
Description: Microscopy for diagnosis of malaria
Study NCT00493922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical diagnosis for malaria
Description: The use of Clinical diagnosis for the diagnosis of malaria
Study NCT02266797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
Study NCT02266797 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
Study NCT00529308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (active)
Description: Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
Study NCT00529308 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (sham)
Description: Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
Study NCT03039530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy
Description: 9 weekly 2-hour group CBT sessions delivered by 2 trained Public Health Nurses.
Study NCT03039530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Postnatal Care As Usual
Description: Postnatal care as usual will involve treatment from their family physician and midwife or obstetrician, and voluntary participation in programs offered by Niagara Region Public Health and in the community.
Study NCT05233748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Resonance (SR)
Description: The system consists of six linear isolated stimulators (STMISOLA, Biopac Systems, Inc., Goleta, USA). The SR signal (Gaussian White Noise, zero mean) will be generated through a 16 bit PCI 6733 National Instruments multifunction data acquisition card by a custom LabView program. The stimulation sites include the ankle, lateral soleus, peroneus longus, and tibialis anterior muscles and the hip.
Study NCT01435083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: 120 µg, oral lyophilisate, sublingual use
Study NCT01722968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
Study NCT01722968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80mg/m2 iv weekly
Study NCT03345238 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling
Description: Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
Study NCT02612311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab: IV infusion
Study NCT02612311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab: IV infusion
Study NCT02612311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202: Oral daily dose
Study NCT02612311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Chlorambucil: Oral dose
Study NCT01409538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Instructions
Description: There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
Study NCT01409538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control condition
Description: This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control.
Study NCT04492254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: The treatment provided will be enoxaparin sodium 40mg/0.4 mL. All doses will be provided in pre-filled, single-dose syringes for subcutaneous injection.
Study NCT03492281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vibegron
Description: single daily oral dose of vibegron 75 mg for 12 weeks
Study NCT03492281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vibegron placebo
Description: placebo to match vibegron (experimental drug)
Study NCT03492281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vibegron placebo
Description: placebo to match vibegron (experimental drug)
Study NCT03492281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine Tartrate ER
Description: single daily oral dose of tolterodine tartrate ER 4 mg for 12 weeks
Study NCT03492281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolterodine placebo
Description: placebo to match tolterodine (active comparator)
Study NCT03492281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine placebo
Description: placebo to match tolterodine (active comparator)
Study NCT04586816 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1% red maple leaf extract in cream base
Description: 1% red maple leaf extract is combined in a cream base
Study NCT04586816 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5% red maple leaf extract
Description: 5% red maple leaf extract is combined in a cream base
Study NCT04586816 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: vehicle
Description: vehicle cream base only
Study NCT02528110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Description: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
Study NCT02528110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 radical gastrectomy
Description: radical gastrectomy with D2 lymphadenectomy
Study NCT02528110 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: D2 radical gastrectomy
Description: radical gastrectomy with D2 lymphadenectomy
Study NCT02528110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOX postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
Study NCT02528110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SOX postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
Study NCT02528110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XELOX postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
Study NCT02528110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: XELOX postoperative chemotherapy
Description: Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
Study NCT03546491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preventive Gel
Description: 0.4% Stannous Fluoride
Study NCT03546491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Control
Description: 0.243% Sodium Fluoride
Study NCT02802514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50mg
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
Study NCT03442686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compass Course
Description: An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
Study NCT01528982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Subjects receive mindfulness training
Study NCT02802514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide matching placebo
Description: It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
Study NCT02802514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 10microgram
Description: It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
Study NCT01528982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognition
Description: Subject receive cognitive training
Study NCT02862457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat 25 mg
Description: Oral administration
Study NCT02802514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide placebo (saline)
Description: It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
Study NCT00903708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2275796
Description: 100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
Study NCT04254523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) of bupicavaine
Description: Programmed intermittent epidural boluses of bupivacaine 0,1% are administered every hour. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
Study NCT04254523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (CEI) of bupivacaine
Description: A continuous epidural infusion of bupivacaine 0,1% is administered at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia. Standardized patient-controlled epidural boluses are available as top-ups.
Study NCT04254523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion (CEI) of morphine
Description: A morphine infusion (0,1mg/ml) is administered in both groups at a prescribed rate. Protocolized adjustments of the dose are performed in order to obtain adequate analgesia.
Study NCT03392597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brothers as Allies
Description: Strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years.
Study NCT03392597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Programming-as-Usual
Description: Usual afterschool programming.
Study NCT01745328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LVX-AMX
Description: Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
Study NCT02862457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg
Description: Oral administration
Study NCT01745328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCM
Description: Subject is treated with TCM for 4 weeks.
Study NCT01745328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LVX-AMX
Description: treatment with placebo from 2 to 4 weeks.
Study NCT03483285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: airtraq videolaryngoscope
Study NCT03483285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: storz
Description: storz videolaryngoscope
Study NCT02862457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg
Description: Intravenous (IV) infusion
Study NCT02862457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m^2
Description: IV infusion
Study NCT02862457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Area Under the Curve (AUC) 5
Description: IV infusion
Study NCT02862457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2
Description: IV infusion
Study NCT02862457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m^2
Description: IV infusion
Study NCT02862457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6
Description: IV infusion
Study NCT00651664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alisertib
Description: Alisertib (MLN8237) capsules
Study NCT02998073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop, Now and Plan
Description: SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
Study NCT01895972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprostene bunod
Study NCT04041362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421
Description: Monoclonal antibody by IV infusion plus standard ART
Study NCT04041362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy (ART)
Description: Standard ART
Study NCT04041362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral Therapy (ART)
Description: Standard ART
Study NCT04518878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Fixed dose of eltrombopag oral 25mg daily
Study NCT04518878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: Rh-TPO 300U/kg subcutaneous injection once daily for 7 consecutive days, followed by a tapering dose in maintenance therapy.
Study NCT02069782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visiting
Description: Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
Study NCT03942458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicagrel 6mg
Description: Vicagrel 24mg loading followed by 6mg/day for 6 days
Study NCT03942458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75mg
Description: Clopidogrel 300mg loading followed by 75mg/day for 6 days
Study NCT02640677 — intervention group
Intervention type: BIOLOGICAL
Intervention: 4CMenB
Description: This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
Study NCT05037045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist
Description: GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
Study NCT03206203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by vein
Study NCT03206203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by vein
Study NCT03206203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker
Description: Correlative study
Study NCT03206203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03948568 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy and Radiotherapy
Description: Endocrine therapy and radiotherapy administered either concurrently or sequentially
Study NCT06231862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SeptiCyte (various)
Description: mRNA expression scores
Study NCT02017340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilvadipine
Description: 8mg of Nilvadipine taken once a day at lunch time for 78 weeks
Study NCT02017340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8mg Placebo tablet taken once a day at lunch time for 78 weeks
Study NCT00930293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)
Description: 16 weekly IPT-PS sessions, each lasting approximately 45 minutes
Study NCT00930293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive Psychotherapy (BSP)
Description: 16 weekly BPS sessions, each lasting approximately 45 minutes
Study NCT00930293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram hydrobromide
Description: A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day